← Human Trials & Peer-Reviewed Studies

The impact of vitamin D supplementation on glycemic control and lipid metabolism in polycystic ovary syndrome: a systematic review of randomized controlled trials.

Plain-language guide to PMID 40259331 (2025): meta-analysis of Vitamin D, K2, Magnesium and Zinc.

Key Facts

PMID
40259331
Journal
BMC endocrine disorders
Year
2025
Study type
Meta-Analysis
Authors
Yu M et al. (5 authors)
DOI
10.1186/s12902-025-01920-5

What This Paper Covers, in Plain Language

What It Covers

Researchers studied Vitamin D, K2, Magnesium and Zinc in this meta-analysis publication.

The purpose of this study is to investigate the impact of vitamin D supplementation on key metabolic parameters-namely blood glucose, insulin, and lipid levels-in individuals with PCOS.

In addition, outcome-related evidence was graded using the GRADE system, and TSA was performed to determine if the number of participants met the required threshold.

Why It Was Studied

Polycystic ovary syndrome (PCOS) is a prevalent endocrine condition affecting both metabolic and reproductive health in women.

The impact of vitamin D on metabolic regulation has attracted growing interest.

Who the Included Studies Covered

PubMed tags the participants as women only.

The search focused on randomized controlled trials (RCTs) evaluating the impact of vitamin D supplementation in patients with PCOS.

How the Review Was Done

A systematic review was conducted to identify relevant studies in PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov.

Meta-analysis was performed using RevMan 5.3 software, and study quality was evaluated with the Cochrane Risk of Bias Tool.

What Was Measured

PubMed files the paper under topics including Polycystic Ovary Syndrome, Vitamin D, Randomized Controlled Trials as Topic, Dietary Supplements, Lipid Metabolism, Glycemic Control and Blood Glucose.

The authors tagged it with the keywords Meta-analysis.

What This Means in Plain Language

This is a meta-analysis of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (BMC endocrine disorders), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.